1 BTC
=
- USD
Akoya BioSciences, Inc. Common Stock
As of May 30, 2026 at 24:05 UTC
Chart
About Akoya BioSciences, Inc. Common Stock
Akoya Biosciences Inc is a life sciences technology company. It is delivering spatial biology solutions focused on transforming discovery, clinical research and diagnostics. Its PhenoCycler (formerly CODEX) and PhenoImager (formerly Phenoptics) platforms, reagents, software, and services, It offer end-to-end solutions to perform tissue analysis and spatial phenotyping across the full continuum from discovery through translational and clinical research and diagnostics.
Market Statistics
Trading Metrics
How to Buy AKYA
Create Your Account
Sign up, deposit BTC, and transfer it to your Unified Trading Account. It only takes a moment.
Start Your Trade
From Terminal, click Trade Now on the asset you want to buy. You'll be purchasing its tokenized asset.
Buy AKYA
Enter the amount and confirm your purchase. That's it! You'll see the impact of the trade in your Unified Trading Account.
New to Tokenized Assets? Learn more in our Help Center.
Latest News
5 articlesThe article discusses the growing cancer treatment market, with a focus on companies like Oncolytics Biotech, Akoya Biosciences, Quanterix, TScan Therapeutics, and Arcellx. It highlights new data and collaborations that signal a turning point for precision-driven cancer biotechs.
Monteverde & Associates PC, a class action law firm, is investigating several proposed mergers, including Akoya Biosciences' merger with Quanterix, Welsbach Technology Metals Acquisition's merger with Evolution Metals LLC, and Playa Hotels & Resorts' merger with Hyatt Hotels Corporation.
The M&A Class Action Firm is investigating the proposed mergers of Global Blue Group Holding, Yotta Acquisition Corporation, Southport Acquisition Corporation, and Akoya Biosciences with other companies. The firm encourages shareholders to act on these mergers.
The global spatial proteomics market is expected to reach $199.8 million by 2030, driven by the growing demand for precision medicine and personalized therapies, particularly in oncology. Key growth drivers include increasing investment in proteomics research and the rising prevalence of chronic diseases.
